Last 1.11 NGN
Change Today -0.05 / -4.31%
Volume 397.3K
As of 9:30 AM 10/24/14 All times are local (Market data is delayed by at least 15 minutes).

neimeth international pharma (NEIMETH) Snapshot

Open
1.16
Previous Close
1.16
Day High
1.16
Day Low
1.11
52 Week High
02/7/14 - 2.38
52 Week Low
11/22/13 - 0.95
Market Cap
1.7B
Average Volume 10 Days
256.2K
EPS TTM
0.10
Shares Outstanding
1.6B
EX-Date
09/22/11
P/E TM
11.1x
Dividend
--
Dividend Yield
--
Current Stock Chart for NEIMETH INTERNATIONAL PHARMA (NEIMETH)

Related News

No related news articles were found.

neimeth international pharma (NEIMETH) Related Businessweek News

No Related Businessweek News Found

neimeth international pharma (NEIMETH) Details

Neimeth International pharmaceuticals plc engages in the manufacture and marketing of pharmaceutical, animal health, and general health care products in Nigeria. It offers consumer products, including analgesics, anthemintiasis, anti-stress/multivitamin, antimalarial/protozoal, antiseptic, and pediatric products; ethical products, which include anti-bacterial, anti-diabetic, anti-fungal, anti-hypertensive, anti-rheumatic, sedative, and sickle cell products; and veterinary products, which include anthelministics, antibiotics, and vitamins. The company offers its products in various forms, such as powders, capsules, syrups, tablets, and creams. It also offers contract manufacturing/analysis services. The company sells its products through distributors. Neimeth International pharmaceuticals plc was founded in 1957 and is headquartered in lkeja, Nigeria.

271 Employees
Last Reported Date: 03/11/14
Founded in 1957

neimeth international pharma (NEIMETH) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

neimeth international pharma (NEIMETH) Key Developments

Neimeth International Pharmaceuticals plc announces Earnings Results for the Year Ended September 30, 2013

Neimeth International Pharmaceuticals plc announced earnings results for the year ended September 30, 2013. For the period, the company reported a turnover of NGN 2,017 billion as against NGN 1,519 billion (adjusted to 12 months) in 2012, showing a growth indices of 33%. With top line revenue of NGN 2,017 billion the company showed an impressive gross margin of NGN 642 million, a growth of 21% over 2012's NGN 529 million (adjusted to 12 months) Profit before tax showed a significant growth of 451%, NGN 183 million, against NGN 52 million in 2012.

Neimeth International Pharmaceuticals plc Announces Board Appointments

The Board of Directors of Neimeth International Pharmaceuticals Plc approved the appointment of directors to handle certain key responsibilities without necessarily being members of the board. These new appointments are with effect from November 1, 2013. Mr. Isaac Igbanoi was appointed Director of Sales Operations. In this new responsibility, Isaac is expected to plan and coordinate Sales cells and Marketing in the newly-restructured Neimeth business. In this new responsibility, Isaac is expected to plan and coordinate Sales cells and Marketing in the newly-restructured Neimeth business. Roseline Akunjeri Oputa is the Director of Administration and Corporate Programmes. Adeyiga Olorunfemi Ojakoya is the company's Director of Strategic Planning & International Markets (STRAPIMS). In this new responsibility, he will focus on business Development, creative and innovative international market penetration, expansion of Neimeth ECOWAS business and ensure the exportation of Neimeth two unique products - NCP and Ciklavit to the USA and Europe. Florence Ifeoma Onyenekwe was appointed General Manager Finance/Company Secretary. She will continue in her current position as company secretary and will be reporting to the Finance Director.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NEIMETH:NL 1.11 NGN -0.05

NEIMETH Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for NEIMETH.
View Industry Companies
 

Industry Analysis

NEIMETH

Industry Average

Valuation NEIMETH Industry Range
Price/Earnings 18.9x
Price/Sales 0.7x
Price/Book 0.8x
Price/Cash Flow 20.3x
TEV/Sales 0.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NEIMETH INTERNATIONAL PHARMA, please visit www.neimethplc.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.